New growth hormone approved for short kids

Article

Insmed Inc. has received the green light from the FDA for iPlex (mecasermin rinfabate [rDNA origin] injection) for the treatment of growth failure in children with severe primary IGF-1 deficiency or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH. According to the Richmond, Va., firm, iPlex is the only approved once-daily IGF-1 replacement therapy available to treat children with short stature.

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Recent Videos
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series
Image Credit: jokekung - stock.adobe.com
Related Content
© 2025 MJH Life Sciences

All rights reserved.